|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
January 28, 2005Mylinax targeted to become first oral therapy for multiple sclerosisJanuary 27, 2005MEMORY PROBLEMS: Alzheimer’s Drug May Help Multiple Sclerosis PatientsAustralian study helps understanding of Multiple SclerosisJanuary 25, 2005Hepatitis B Vaccination Increases Multiple Sclerosis RiskYoga, Exercise Improve Fatigue Associated With MSJanuary 21, 2005
[FDA NEWS] "First Monoclonal Antibody Treatment For MS Approved"...Tysabri: "First Monoclonal Antibody Treatment For MS Approved"
January 20, 2005
[Tysabri] FDA NEW RELEASE: FDA has licensed a new biologic approach to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of symptom flare-ups or exacerbations of the disease.FDA has licensed a new biologic approach to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of symptom flare-ups or exacerbations of the disease.
January 10, 2005MS PODCAST: PRODUCED BY THE MD HEALTH CHANNELJanuary 02, 2005
FDA Approves Tysabri: "Because of positive data from clinical trials, the FDA approved Tysabri—formerly called Antegren—after only one year of study. Usually, two years of trials are required before approving a new drug.Trial results a 66% reduction in the relapse rate of MS symptoms in patients studied when compared with placebo."
January 01, 2005
[Tysabri] Formerly known as Antegren: The Maryland Center for Multiple Sclerosis
|